Rappta
4 known investors
Find your way into Rappta
Sign up to see every warm intro you have to Rappta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rappta team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function. The company targets the underlying mechanism of protein hyperphosphorylation that drives cancer progression.
Investors · 4
How we know: Advent Life Sciences's portfolio page · funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: funding news · pharmaceutical-technology.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2020
Novartis Venture Fund (lead), Novo Holdings (lead), Novo Seeds (lead), Advent Life Sciences
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Rappta do?
- Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function. The company targets the underlying mechanism of protein hyperphosphorylation that drives cancer progression.
- Who are Rappta's investors?
- Rappta's investors include Advent Life Sciences, Novartis Venture Fund, Novo Holdings.
